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A previously unknown side eﬀect of biphosphonate use is emerging. In a speciﬁc patient group on long term biphosphonate
therapy stress femur fractures seem to occur. The typical presentation consists of prodromal pain in the aﬀected leg and/or a
discrete cortical thickening on the lateral side of the femur in conventional radiological examination or the presentation with a
spontaneous transverse subtrochanteric femur with typical features. We present three cases of this stress fracture in patients on
bisphosphonate therapy. One of these patients suﬀered a bilateral femur fracture of the same type. In our opinion, in patients on
bisphosphonate therapy who present with a spontaneous femur fracture, seizing therapy is advisable. In bilateral cases preventive
nailing should be considered.
Copyright © 2009 M. P. Somford et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Following earlier reports of spontaneous femur fracture in
patients using alendronate, we present three cases with a
similar course. All three of these patients presented with
typical prodromal symptoms resulting in a speciﬁc fracture
type discussed afterwards.
1.1. Case 1. Patient A, a 65-year-old woman, was seen at
the emergency room with sudden pain in her right leg after
getting up from a chair and an inability to bear weight. Her
medical history showed rheumatoid arthritis since 2001 and
hypertension. The medication list consisted of alendronate
sodium 70mg o.w. for four years, omeprazole 20mg o.d.,
prednisone 10mg o.d. for seven years, and metoprolol
100mg o.d., plaquenil 200mg t.d., etanercept 50mg o.w.
Four months prior to the patient’s visit to the emergency
room, the rheumatologist had consulted the neurologist and
the orthopaedic surgeon because of persisting pain in the
right leg and groin, but no neurological or orthopaedic
explanation could be found. The only abnormality found
was a thickening of the medial and lateral cortex of the right
femur with a discrete local periostal reaction on the lateral
cortex (Figure 1). Laboratory results were normal.
Radiological examination on admission showed a trans-
verse subtrochanteric fracture of the right femur with a
medial spike. The fracture was located at the same spot as
the cortical thickening (Figure 2).
A closed reduction and internal ﬁxation took place. The
patient was discharged from the hospital in good condition a
week later.
1.2. Case 2. Patient B, a 79-year-old woman, was seen at
the emergency room because of a sudden inability to bear
weight on her left leg. The patient related that she had heard
a crack in her leg and had then fallen down. Her medical
history showed osteoporosis and rheumatoid arthritis since
1987. The medication list consisted of prednisone 5mg o.d.
for 8 years, alendronic acid 70mg o.w. for 12 years, calcium
carbonate 500mg o.d., methotrexate 20mg o.w. for 7 years,
furosemide 40mg o.d., etoricoxib 60mg o.d., potassium
chloride 1200mg o.d., lansoprazole 30mg o.d., carvedilol
6.25mg o.d., acenocoumarol, gliclazide 30mg o.d., folic acid
10mg o.w., and tramadole 100mg o.d.2 International Journal of Rheumatology
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Figure 1: X-ray taken at ﬁrst presentation of thigh pain on the right
side. There is a sign of discrete lateral cortex thickening.
L
Figure 2: The subtrochanteric fracture through the lateral cortex
thickening with a medial spike.
Prior to the patient’s visit to the emergency room, the
rheumatologist had referred her to the orthopaedic surgeon
because of pain in the left thigh. Radiological examination at
thattimeshowedathickeningofthemedialandlateralcortex
oftheleftfemurwithadiscretelocalperiostalreactiononthe
lateral cortex (Figure 3). A bone scintigraphy showed a small
focal lesion in the left femoral midshaft, and an additional
computer tomography (CT) scan revealed a small thickening
of the cortex at the level of the hotspot.
On physical examination in the emergency room, a
diﬀuse swollen left thigh was noted with evident pain when
stress was applied through the femur. Laboratory results
were normal. Additional radiological examination showed a
transverse femur shaft fracture (Figure 4). The fracture site
was at the exact location of the cortical thickening.
L
Figure 3: Cortical thickening (arrow) at the site of the pain in the
left thigh.
Closed reduction and internal ﬁxation took place. Bone
collected after reaming of the femur was sent out for
pathological examination. The pathological examination
showed small fragments of cancellous bone tissue and bone
marrow without signs of malignancy, the aspect of normal
bone.
1.3. Case 3. Patient C, a 76-year-old woman, was admitted
to hospital by the rheumatologist because of persisting pain
in her left leg without a clear diagnosis. Her medical history
showed rheumatoid arthritis since 1985. The medication list
consisted of prednisone 5mg o.d. for 9 years, omeprazole
20mg o.d., alendronate sodium 70mg o.w. for 12 years,
methotrexate 15mg o.w. for 8 years, folic acid 5mg o.w. and
inﬂiximab infusion 200mg once per 8 weeks for 3 years.
The patient’s complaints of leg pain had started approx-
imately three months earlier without any preceding trauma.
Since the start of the leg complaints, she had not been able
to walk more than a few steps at a time. The neurologist
was consulted but no neurological explanation was found.
As blood samples, including hydroxyvitamin D, showed no
abnormalities, the orthopaedic surgeon was consulted.
Radiological examination of the pelvis and left upper-leg
showed a thickening of the medial and lateral cortex with
a discrete thickening of the cortex on the lateral side of the
proximal femur (Figure 5). A bone scintigraphy showed a
hotspot in the left femur. Single-photon emission computerInternational Journal of Rheumatology 3
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Figure 4: The subtrochanteric fracture through the thickening of
the lateral cortex with a medial spike.
tomography (SPECT) of this region also demonstrated a dis-
crete thickening of the cortex without changes of the periost.
The cortex was intact both internally and externally and
showed increased thickness (Figure 6). An additional dual-
energy X-ray absorptiometry (DEXA) scan of the lumbar
vertebrae showed no signs of osteoporosis or osteopenia (T-
score 0.1).
Before any more tests could be performed, the patient
heard a crack when she attempted to sit down on a
chair. This turned out to be a transverse subtrochanteric
fracture through the cortical thickening with a medial spike
(Figure 7).Closedreductionandinternalﬁxationtookplace.
A biopsy taken intraoperatively showed blood and fat
with a normal haematopoiesis microscopically. Additional
immunohistochemical investigation showed no signs of
malignancy or osteoporosis. After the operation, the patient
very quickly regained mobility and was free of pain.
The patient reappeared at the emergency room eight
months later. She was using the same medication as before,
except for the methotrexate. The patient had been suﬀering
from pain in her right thigh for two weeks and had sustained
a spontaneous subtrochanteric fracture of the right femur
while walking (Figure 8). Upon examination it turned out
that the patient had again suﬀered a transverse fracture at
the exactlocation ofa corticalthickening. A closed reduction
and internal ﬁxation took place. Postoperatively, the patient
very quickly regained mobility and was discharged from the
hospital after ten days.
L
Figure 5: Thickening of the lateral cortex (arrow) at the site of the
pain in the left thigh.
2. Discussion
Since their introduction in The Netherlands in 1996, bis-
phosphonates are often prescribed for the prevention and
treatment of osteoporosis. General practitioner’s guidelines
mention it along with calcium and vitamin D as the
preferred preventive medical treatment [1]. One of the
guidelines’ core messages is that patients with long-term
use of corticosteroids as well as patients with osteoporo-
sis could be treated with bisphosphonates (alendronate
and risendronate). Bisphosphonates act as bone resorption
inhibitors inhealthyindividuals aswellasinindividuals with
increased resorption, in whom they can restore the balance
[2].
The guidelines advise against prescribing bisphospho-
nates for longer than ﬁve years as data on the long-
term eﬀects of bisphosphonates are lacking. However, they
do recommend continuing the use of bisphosphonates in
patients with long-term use of corticosteroids. In these
patients, the bisphosphonates should only be discontinued
at the same time as the corticosteroids [1].
Recently, several reports have warned for the possible
negative eﬀects of long-term alendronate use. These reports
associate long-term alendronate use with subtrochanteric
fractures. It has been known for a long time that the
subtrochanteric region is subjected to maximal bending
stress and is, as such, the strongest part of the femur [3].
Consequently, a fracture in this region following low-
energy trauma seems unlikely. Only 10–34% of all proximal
f e m u rf r a c t u r e so c c u ri nt h es u b t r o c h a n t e r i cr e g i o n[ 4].
In a retrospective study, Goh et al. describe a group
of 13 Asian female patients who presented with low-energy
subtrochantericfractures[5].Ninepatientsweretakingalen-
dronate. There was a clear diﬀerence in age and fracture type
betweenpatientswhousedalendronateandpatientswhodid
not. Those using alendronate mainly presented with a simple4 International Journal of Rheumatology
Figure 6: SPECT of the lesion on the left femur showing bilaterally thickened cortices and both internally and externally intact cortices. On
the left side the bone scan showing a hotspot on the lateral side of the left femur.
transverse fracture at a mean age of 66.9 years. The other
patientspresentedwithmorecomminutivefracturesandhad
an average age of 80.3 years. The average use of alendronate
was 4.2 years (range 2.5–5 years). Remarkably, ﬁve of the
women who used alendronate reported experiencing pain in
the fractured limb two to six months prior to the injury.
Patients without alendronate use did not experience these
prodromal symptoms.
Neviaser et al. collected data retrospectively on 70 low-
energy femoral shaft fractures [6]. In this group, 25 female
patients (23 Caucasian and 2 Asian) used alendronate. The
averageperiodthatalendronatewasusedwas6.2years(range
1–10 years). Data analysis showed that 76% of the patients
using alendronate had a speciﬁc fracture pattern, which was
seen in only 2% of the patients without alendronate use. This
fracture pattern consists of a simple transverse fracture of
the femur with a unicortical spike in an area of hypertrophy.
Furthermore, it was calculated that such a fracture pattern
is 98% speciﬁc for alendronate-using patients. It is worth
noting that in the alendronate group the patients that did
display the fracture pattern had been using alendronate
signiﬁcantly longer (6.9 years versus 2.5 years for short-term
users).
The same speciﬁc fracture pattern is also described
by Kwek et al. [7]. They carried out a retrospective study
on 17 Asian female patients with low-energy trauma sub-
trochanteric fractures. All patients had received alendronate
therapyforameanof4.4years(rangeof2–8years).Theaver-
age age of the patients was 66 years (range of 53–82 years).
Prodromal symptoms were present in 13 patients (76%).
Six patients had a stress zone in the subtrochanteric region
of the contra-lateral femur. Four patients sustained bilateral
subtrochanteric fractures. The aﬀected region might just be
due to the maximal bending stress of the subtrochanteric
region, especially the lateral cortex [3].
In the three cases related above, the patients are all
female and are respectively 65, 76, and 79 years of age.
They are all long-term alendronate users. In our group an
average use of 10 years (range of 4–13 years) is present.
Following the Dutch general practitioner’s guidelines, they
should use alendronate for an extended period as long as
they are using corticosteroids too. All three patients showed
the typical prodromal symptoms and a thickening of the
lateral cortex that resulted in subtrochanteric fractures. The
fractures were not caused by any trauma and might be
described as spontaneous fractures. But in our opinion the
thickening of the cortex prior to the fracturing of the femur
makesitastressorfatiguefracture.Thisevolvingofacortical
thickening into a (fatigue) fracture is particularly clear in
our third case. The fracture patterns itself accorded with the
typical pattern described by Kwek et al. [7]. Additionally,
the prodromal complaints and cortical thickening ﬁtted the
cases described by Goh et al. [5]a n dK w e ke ta l .[ 7].
We ﬁnd it very peculiar that radiologically there seemed
to be no sign of osteoporosis. The radiological examination
of the femurs showed a thick cortex and small lumen of
the femur, while osteoporotic bone typically shows cortical
thinning and increased radiolucency. The DEXA scan inInternational Journal of Rheumatology 5
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Figure 7: Fracture through the thickening of the lateral cortex with
a medial spike.
R
Figure 8: Subtrochanteric fracture in the same patient as Figures
5 and 6 o nt h ec o n t r a - l a t e r a ls i d e .T h ef r a c t u r eh a st h ee x a c ts a m e
pattern.
our third case did not show any sign of osteoporosis or
osteopenia.
Additionally, there was no sign of fracture at the time
of the periosteal reaction. This reaction is most likely
due to microfractures at these high stressed points in the
skeleton that produce a callus osteoid (so-called Looser’s
transformation).
The patients in the cases were receiving more types
of medication than only the bisphosphonates. If the other
medication is of any inﬂuence on the fractures remains
questionable. Corticosteroids are known to cause fractures
with preserved bone density. Also can corticosteroids induce
apoptosis in osteoblasts and clasts thus resulting in osteo-
porosis and related fractures [8]. But it concerns vertebral
fractures and hip fractures and no cases of subtrochanteric
fractures have been described, hence the possibility of
corticosteroids causing these fractures is highly improbable
[9]. The same goes for proton pump inhibitors causing
osteoporotic fractures [10]. But still, no cases are known
with normal BMD and subtrochanteric fractures in chronic
PPI use. The inﬂuence of methotrexate on bone metabolism
is not known, but in our cases 1 patient did not use
methotrexate at all.
In the pathology reports of the taken biopsies in patients
two and three, there were no signs of hypermineralization
or micro fractures. It was remarkable that there was a
normal concentration of osteoclasts while bisphosphonates
are assumed to inhibit osteoclasts. Also there was an
imbalance between bone formation and bone resorption,
resulting in increased resorption. This is in contrast with the
presumption that these fractures are caused by suppressed
bone turnover [11].
We have a strong suspicion but no deﬁnite evidence,
backed by recent reports [12–15], that there might be a
causal relation between long-term alendronate use and low-
energy subtrochanteric fractures with prodromal pain. The
course of the aforementioned cases seems reason enough to
discontinue alendronate and to strictly follow-up the patient
in order to prevent a fracture on the contra-lateral side,
even, or perhaps especially, in patients using prednisone as
well. Discontinuation does not signiﬁcantly change the risk
of non-vertebral fracture in the ﬁrst 5 years. In a group of
women with discontinued therapy after 5 years, the BMD
remained at or above baseline values 10 years earlier and
bone turnover was still somewhat reduced [16].
Furthermore, it should be noted that a negative DEXA
scan and a thick cortex on radiological examination do not
exclude the possibility of spontaneous fracture in a speciﬁc
population. Additional research is necessary to determine
the exact correlation between the use of alendronate and
spontaneous or low-energy trauma fractures.
3. Conclusion
At the annual meeting of the American Academy of
Orthopaedic Surgeons on the 11th of March 2008, Goh and
Neviaser warned for the risks of fractures in alendronate
use. They stated that further research on the negative eﬀects
of long-term alendronate use is necessary. In addition, they
argued that the above mentioned fracture pattern in an
area of cortical thickening could be speciﬁc to alendronate-
using patients. In our opinion, the fractures seen are most
appropriately named stress or fatigue fractures. In this
view, patients with these prodromal symptoms should at
least refrain from weight bearing of the aﬀected limb. The6 International Journal of Rheumatology
alendronate should be discontinued. In case of bilateral
symptoms, resulting in inability to mobilise without weight
bearing, or inability to refrain from weight bearing for any
other reason, preventive nailing should be considered. It
remains unknown whether changed calciﬁcation results in
loss of elasticity or whether the cellular response to micro-
fractures in the area of the femur subjected to maximal
bending stress is disturbed.
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